Zimmer Biomet Holdings, Inc.’s Stock Price Drops to $97.27, Witnessing a 4.61% Decrease: A Deep Dive into ZBH’s Market Performance

Zimmer Biomet Holdings, Inc. (ZBH)

97.27 USD -4.70 (-4.61%) Volume: 2.34M

Zimmer Biomet Holdings, Inc.’s stock price is currently standing at 97.27 USD, experiencing a downturn this trading session with a percentage change of -4.61%. The stock, with a trading volume of 2.34M, has seen a negative year-to-date performance, posting a percentage change of -7.91%.

Latest developments on Zimmer Biomet Holdings, Inc.

Zimmer Biomet Holdings Inc. stock has been underperforming compared to its competitors, with the stock touching a 52-week low at $97.62. Despite this, the company is making moves to potentially protect its officers, as it proposes an Officer Exculpation Amendment at an upcoming shareholder meeting. Additionally, Zimmer Biomet recently filed an SEC Form DEFA14A, indicating potential changes on the horizon. Despite the stock’s struggles, there is some optimism as BTIG raises Zimmer Biomet’s price target to $123 from $122, possibly indicating a positive outlook for the MedTech sector.

Zimmer Biomet Holdings, Inc. on Smartkarma

Analysts on Smartkarma, such as Special Situation Investments, have provided bullish insights on Zimmer Biomet Holdings. In their report titled “Paragon 28 Acquisition by Zimmer Biomet: Evaluating the Free CVR Opportunity and Growth Potential,” they highlight the acquisition of Paragon 28 by Zimmer Biomet for $13/share in cash plus a non-transferable CVR tied to 2026 revenue. The CVR offers potential upside of up to $1/share if Paragon’s revenue reaches $361m, with manageable growth targets. The merger is seen as well-supported by management and faces few regulatory obstacles, making it an attractive opportunity for investors.

A look at Zimmer Biomet Holdings, Inc. Smart Scores

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

According to Smartkarma Smart Scores, Zimmer Biomet Holdings is looking at a positive long-term outlook. The company scores highly in areas such as value, growth, and momentum, indicating a strong performance in these aspects. With a focus on designing, developing, and manufacturing medical equipment for orthopedic, dental, and spinal reconstructive implants, Zimmer Biomet Holdings is poised to continue serving patients worldwide with innovative products.

Additionally, Zimmer Biomet Holdings shows resilience in the face of challenges, scoring well in this category. While the dividend score is not as high as other factors, the overall outlook for the company remains promising. Investors and stakeholders can take note of the Smartkarma Smart Scores to gain insights into Zimmer Biomet Holdings’ performance and potential for future growth in the medical equipment market.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma